Updated interim results of phase 2 trial of pembrolizumab for high-risk NMIBC unresponsive to BCG Presented ByProf. Ashish Kamat, MD Anderson Cancer Center, Houston, USA TrialKEYNOTE-057, KEYNOTE-676 ConferenceEAU 2019 21 May, 2019 17:01